Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
1(13%)
Results Posted
0%(0 trials)

Phase Distribution

Ph early_phase_1
1
13%
Ph not_applicable
1
13%
Ph phase_2
1
13%
Ph phase_3
2
25%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(5)
Terminated(1)
Other(1)

Detailed Status

Completed5
Withdrawn1
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 32 (40.0%)
N/A1 (20.0%)

Trials by Status

withdrawn113%
recruiting113%
completed563%
unknown113%

Recent Activity

1 active trials
Showing 5 of 8
completednot_applicable

Markers of Disease Progression and Gait Within the Parkinsonian Population

NCT04653688
recruiting

Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

NCT03019757
completedphase_2

Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression

NCT01141023
completedearly_phase_1

Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain

NCT03058965
unknown

Nigrosomal Iron Imaging in Parkinson's Disease

NCT03022357
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04653688Not Applicable

Markers of Disease Progression and Gait Within the Parkinsonian Population

Completed
NCT03019757

Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

Recruiting
NCT01141023Phase 2

Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression

Completed
NCT03058965Early Phase 1

Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain

Completed
NCT03022357

Nigrosomal Iron Imaging in Parkinson's Disease

Unknown
NCT01950468Phase 3

A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Withdrawn
NCT02572713

Systemic Synuclein Sampling Study (S4)

Completed
NCT00209456Phase 3

Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia

Completed

All 8 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
8